Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helmut Butzkueven

Showing results (191-200 of 390) with videos related to

Pageof 39
Sort By:
Human Genetics|March 12, 2004
Extended haplotype analysis in the HLA complex reveals an increased frequency of the HFE-C282Y mutation in individuals with multiple sclerosisJustin P Rubio, Melanie Bahlo, Niall Tubridy, et al.
Nature Reviews. Neurology|July 23, 2025
Advancing multiple sclerosis management in older adultsAnneke van der Walt, Eva M M Strijbis, Francesca Bridge, et al.
Multiple Sclerosis and Related Disorders|June 27, 2025
Brain health - time matters: multiple sclerosis, neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and related conditions. 2024 reportHelmut Butzkueven, Sofia Arkelsten, Giancarlo Comi, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 27, 2022
Prediction of relapse activity when switching to cladribine for multiple sclerosisMichael Zhong, Anneke van der Walt, Mastura Monif, et al.
Clinical Drug Investigation|March 18, 2022
Multiple Sclerosis Relapses Following Cessation of FingolimodCharles B Malpas, Izanne Roos, Sifat Sharmin, et al.
International Journal of MS Care|June 28, 2021
Patient Preferences for Time and Location of Infusible Therapies in Multiple Sclerosis and Neuroimmunologic DisordersLouise Rath, Maria Pia Campagna, Jim Stankovich, et al.
Multiple Sclerosis and Related Disorders|December 11, 2024
RENEWED: A follow-up study of the opicinumab phase 2 RENEW study in participants with acute optic neuritisOrhan Aktas, Focke Ziemssen, Tjalf Ziemssen, et al.
European Journal of Neurology|August 16, 2023
The Patient-Determined Disease Steps scale is not interchangeable with the Expanded Disease Status Scale in mild to moderate multiple sclerosisYi Chao Foong, Daniel Merlo, Melissa Gresle, et al.
Neurology and Therapy|July 24, 2024
Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (Tysabri<sup>®</sup>) Dosing: NOVA Phase IIIb Extension Study (Part 2)Heinz Wiendl, John Foley, Gilles Defer, et al.
Clinical Immunology (Orlando, Fla.)|March 13, 2024
The immune cell transcriptome is modulated by vitamin D<sub>3</sub> supplementation in people with a first demyelinating event participating in a randomized placebo-controlled trialWei Zhen Yeh, Melissa Gresle, Rodney Lea, et al.
Pageof 39

Showing results (191-200 of 390) with videos related to

Sort By:
Pageof 39
Human Genetics|March 12, 2004
Extended haplotype analysis in the HLA complex reveals an increased frequency of the HFE-C282Y mutation in individuals with multiple sclerosisJustin P Rubio, Melanie Bahlo, Niall Tubridy, et al.
Nature Reviews. Neurology|July 23, 2025
Advancing multiple sclerosis management in older adultsAnneke van der Walt, Eva M M Strijbis, Francesca Bridge, et al.
Multiple Sclerosis and Related Disorders|June 27, 2025
Brain health - time matters: multiple sclerosis, neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and related conditions. 2024 reportHelmut Butzkueven, Sofia Arkelsten, Giancarlo Comi, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 27, 2022
Prediction of relapse activity when switching to cladribine for multiple sclerosisMichael Zhong, Anneke van der Walt, Mastura Monif, et al.
Clinical Drug Investigation|March 18, 2022
Multiple Sclerosis Relapses Following Cessation of FingolimodCharles B Malpas, Izanne Roos, Sifat Sharmin, et al.
International Journal of MS Care|June 28, 2021
Patient Preferences for Time and Location of Infusible Therapies in Multiple Sclerosis and Neuroimmunologic DisordersLouise Rath, Maria Pia Campagna, Jim Stankovich, et al.
Multiple Sclerosis and Related Disorders|December 11, 2024
RENEWED: A follow-up study of the opicinumab phase 2 RENEW study in participants with acute optic neuritisOrhan Aktas, Focke Ziemssen, Tjalf Ziemssen, et al.
European Journal of Neurology|August 16, 2023
The Patient-Determined Disease Steps scale is not interchangeable with the Expanded Disease Status Scale in mild to moderate multiple sclerosisYi Chao Foong, Daniel Merlo, Melissa Gresle, et al.
Neurology and Therapy|July 24, 2024
Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (Tysabri<sup>®</sup>) Dosing: NOVA Phase IIIb Extension Study (Part 2)Heinz Wiendl, John Foley, Gilles Defer, et al.
Clinical Immunology (Orlando, Fla.)|March 13, 2024
The immune cell transcriptome is modulated by vitamin D<sub>3</sub> supplementation in people with a first demyelinating event participating in a randomized placebo-controlled trialWei Zhen Yeh, Melissa Gresle, Rodney Lea, et al.
Pageof 39